Evidence map›Paper›PMID 34019179›Full record

ArticleVirchows Archiv : an international journal of pathology2021

CD73 expression in normal, hyperplastic, and neoplastic thyroid: a systematic evaluation revealing CD73 overexpression as a feature of papillary carcinomas.

Inês Monteiro, Edoardo Missiaglia, Amedeo Sciarra, João Vasco Santos, Justine Bouilly, Pedro Romero, Christine Sempoux, Laurence de Leval

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. CD73 mitigates ZEB1 expression in papillary thyroid carcinoma.Cell communication and signaling : CCS · 2024
    Article
  4. Review
  5. Purinergic signaling in thyroid disease.Purinergic signalling · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Inês Monteiro *Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Rue du Bugnon 25, CH-1011, Lausanne, Switzerland.
Edoardo Missiaglia *Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Rue du Bugnon 25, CH-1011, Lausanne, Switzerland.
Amedeo Sciarra *Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Rue du Bugnon 25, CH-1011, Lausanne, Switzerland.
João Vasco SantosMEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.
Justine BouillyInstitute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Rue du Bugnon 25, CH-1011, Lausanne, Switzerland.
Pedro RomeroDepartment of Fundamental Oncology, University of Lausanne, Lausanne, Vaud, Switzerland.
Christine SempouxInstitute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Rue du Bugnon 25, CH-1011, Lausanne, Switzerland.
Laurence de LevalInstitute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Rue du Bugnon 25, CH-1011, Lausanne, Switzerland. laurencedeleval@chuv.ch.ORCID http://orcid.org/0000-0003-3994-516X
University of Lausanne · CHHôpital du Valais · CHUniversidade do Porto · PT

Funding

FP7/2007-2013 602200
6 · The paper itself

Abstract

CD73 converts AMP to adenosine, an immunosuppressive metabolite that promotes tumorigenesis. This study presents a systematic evaluation of CD73 expression in benign, hyperplastic, and neoplastic thyroid. CD73 expression was assessed by immunohistochemistry in 142 thyroid samples. CD73 was expressed in normal thyroid (3/6) and goiter (5/6), with an apical pattern and mild intensity. Apical and mild CD73 expression was also present in oncocytic cell adenomas/carcinomas (9/10; 5/8) and in follicular adenomas/carcinomas (12/18; 23/27). In contrast, papillary thyroid carcinomas featured extensive and intense CD73 staining (49/50) (vs. normal thyroid/goiter, p < 0.001). Seven of nine anaplastic carcinomas were CD73-positive with heterogeneous extensiveness of staining. Medullary and poorly differentiated carcinomas were mostly CD73-negative (1/6; 2/2). These results were corroborated by NT5E mRNA profiling. Papillary carcinomas feature enhanced CD73 protein and mRNA expression with distinct and intense staining, more pronounced in the invasive fronts of the tumors.

Indexed as

5'-NucleotidaseAdenomaBiomarkers, TumorCase-Control StudiesGene Expression Regulation, NeoplasticGoiterGPI-Linked ProteinsHumansHyperplasiaImmunohistochemistryPredictive Value of TestsThyroid Cancer, PapillaryThyroid NeoplasmsUp-Regulation5'-NucleotidaseBiomarkers, TumorGPI-Linked ProteinsNT5E protein, humanCD73ImmunohistochemistryPapillary thyroid carcinomaThyroid adenomaThyroid carcinoma

Identifiers

PMID34019179
PMCPMC8298324
OpenAlexW3160138598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.